Phase I clinical and pharmacokinetic study of oral penclomedine (NSC 338720) in adults with advanced solid malignancy

Clinical Cancer Research

Volumn 8, Issue 3, 2002, Pages 706-711

  Liu, Glenn ^a   Berlin, Jordan ^a   Tutsch, Kendra D ^a   Van Ummersen, Lynn ^a   Dresen, Amy ^a   Marnocha, Rebecca ^a   Arzomanian, Rhoda ^a   Alberti, Dona ^a   Feierabend, Chris ^a   Binger, Kimberly ^a   Wilding, George ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 O DEMETHYLPENCLOMEDINE; DRUG METABOLITE; PENCLOMEDINE; PICOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; ATAXIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG PENETRATION; DRUG WITHDRAWAL; DYSMETRIA; FEMALE; HUMAN; LYMPHOMA; MALE; MAXIMUM TOLERATED DOSE; NEUROTOXICITY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CEREBELLAR ATAXIA; DIZZINESS; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NAUSEA; NEOPLASMS; PICOLINES;

EID: 0036307690     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Preclinical antitumor activity of an α-picoline derivative, penclomedine (NSC-338720), on human and murine tumors
2. Preclinical antitumor activity of penclomedine in mice: Cross-resistance, schedule dependence, and oral activity against tumor xenografts in brain
3. Biochemical pharmacology of penclomedine (NSC-338720)
4. Murine pharmacokinetics and metabolism of penclomedine [3,5-dichloro-2,4-dimethyl-6-(trichloromethyl)pyridine, NSC 338720]
5. Murine and human in vivo penclomedine metabolism
6. Phase I and pharmacologic study of penclomedine, a novel alkylating agent, in patients with solid tumors
7. Phase I clinical and pharmacokinetic trial of penclomedine using a novel, two-stage trial design for patients with advanced malignancy
8. Dose-limiting neurotoxicity in a Phase I study of penclomedine (NSC 388720, CRC 88-04), a synthetic α-picoline derivative, administered intravenously
9. 14C-penclomedine in rats
10. Toxicity of five-hour intravenous infusion of penclomedine (PEN, NSC-338720) in beagle dogs